Healthcare -
Biotechnology - NASDAQ - US
$ 37.25
-0.268 %
$ 5.85 B
Market Cap
248.33
P/E
1. INTRINSIC VALUE
Balance Sheet
TG Therapeutics, Inc.
| Current Assets | 566 M |
| Cash & Short-Term Investments | 311 M |
| Receivables | 129 M |
| Other Current Assets | 126 M |
| Non-Current Assets | 11.3 M |
| Long-Term Investments | 808 K |
| PP&E | 7.15 M |
| Other Non-Current Assets | 3.37 M |
| Current Liabilities | 90.7 M |
| Accounts Payable | 0 |
| Short-Term Debt | 1.16 M |
| Other Current Liabilities | 89.5 M |
| Non-Current Liabilities | 265 M |
| Long-Term Debt | 253 M |
| Other Non-Current Liabilities | 12.1 M |
EFFICIENCY
Earnings Waterfall
TG Therapeutics, Inc.
| Revenue | 329 M |
| Cost Of Revenue | 38.5 M |
| Gross Profit | 291 M |
| Operating Expenses | 249 M |
| Operating Income | 41.9 M |
| Other Expenses | 18.5 M |
| Net Income | 23.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
TG Therapeutics, Inc.
| Net Income | 23.4 M |
| Depreciation & Amortization | 68 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 42.5 M |
| Change in Working Capital | -109 M |
| Others | 15.6 M |
| Free Cash Flow | -40.5 M |
Wall Street Analysts Price Targets
TG Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for TGTX of $41.3 , with forecasts ranging from
a
low of
$20 to a high of $55 .
TGTX Lowest Price Target
Wall Street Target
20 USD
-46.31%
TGTX Average Price Target
Wall Street Target
41.3 USD
10.96%
TGTX Highest Price Target
Wall Street Target
55 USD
47.65%
4. DIVIDEND
ANALYSIS
TGTX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
TG Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
2.03 M USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
433 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the experience of seven individuals with MS who switched to BRIUMVI® (ublituximab-xiiy) from a different anti-CD20 monoclonal antibody therapy due to efficacy or tolerability concerns. Details of the publications are provided below.
globenewswire.com
- 2 weeks ago
These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles
Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating.
investors.com
- 1 month ago
Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher
Trading is subdued with TG Therapeutics, Inc. TGTX on Friday. But the shares remain in an uptrend and there is a good chance the trend will continue.
benzinga.com
- 1 month ago
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?
TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
zacks.com
- 1 month ago
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel
Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and autoimmune disorders. TG Therapeutics' BRIUMVI achieved significant sales growth in 2024, supporting positive cash flow and funding for future developments, including azer-cel for autoimmune disorders. DTIL is rated a speculative "Buy" due to its undervaluation, promising pipeline, and strategic partnerships, while TGTX is rated "Hold" due to its full valuation.
seekingalpha.com
- 1 month ago
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy.
seekingalpha.com
- 1 month ago
TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter
TGTX's Briumvi, despite initial struggles, has shown strong performance by consistently beating earnings estimates, even with competition from Roche's Zunovo. Briumvi's competitive advantages include a shorter infusion time, lower malignancy risks, and a more favorable price compared to Ocrevus. TGTX's financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite cash runway.
seekingalpha.com
- 1 month ago
S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout
These watch list stocks have beenholding near buy points while the market has been breaking down. The post S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout appeared first on Investor's Business Daily.
investors.com
- 1 month ago
Why TG Therapeutics Stock Was Soaring This Week
Following news of an estimates-topping fourth quarter, TG Therapeutics (TGTX 9.24%) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intelligence, as of mid-afternoon Friday, the biotech's share price had risen by almost 27% week to date.
fool.com
- 1 month ago
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting, being held April 5 - 9, 2025, in San Diego, California. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. Details of the upcoming presentations are outlined below.
globenewswire.com
- 1 month ago
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025
With the broader market facing volatility, a clutch of experts are recommending investors to look beyond mega-cap stocks like Meta, Amazon, and Netflix for opportunities in stocks with strong earnings growth potential.
invezz.com
- 1 month ago
TG Therapeutics: A Wonderful Hold
TG Therapeutics, Inc. stock is surging due to strong financial performance and a promising outlook, driven by the success of its flagship drug, Briumvi. Revenue for Q4 reached $107.3 million, up 146% year-over-year with 2024 total revenue at $313.7 million, largely from Briumvi sales. The company achieved a net income of $23.3 million in Q4, a significant turnaround from a net loss in the previous year, with positive cash flow.
seekingalpha.com
- 1 month ago
8. Profile
Summary
TG Therapeutics, Inc. TGTX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 5.85 B
Dividend Yield
0.00%
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Contact
2 Gansevoort Street, New York, NY, 10014
https://www.tgtherapeutics.com
IPO
Date
May 3, 2010
Employees
338
Officers
Ms. Jenna Bosco
Senior Vice President of Corporate Communications
Mr. Adam Waldman
Chief Commercialization Officer
Mr. Michael S. Weiss Esq.
Chairman, Chief Executive Officer & President